Indian Non-Hodgkin Lymphoma Drugs Market size stood at around USD XX billion in 2019 and is projected to reach USD XX billion by 2028, exhibiting a CAGR of XX% during the forecast period.
Non-Hodgkin lymphoma is a type of cancer that has an effect on the white blood cells of the human body. The disease reduces the immunity of the human body. The severity of the disease has led to a huge emphasis on the R&D of treatment methods. As a result, high investments are being made towards developing efficient treatment methods. The high prevalence of the disease across the world has also caught the eye of investors. There are numerous clinical trials associated with the treatment of the diseases. Its treatment varies with fast or slow growth of the cells, and depends on whether it is spread across one area or different areas of the body. Various treatment options for NHL include immunotherapy, chemotherapy, stem cell transplantation, targeted therapy, monoclonal antibody therapy, and radiation therapy. Moreover, there are numerous products available for treating this condition, for example, Deltasone, Adcertis, Folotyn, Adriamycin, Prednicot, Leukeran, Velcade, Thioplex, and Decadron. Various small molecule-targeted therapies, such as idelalisib and ibrutinib, are the latest advancements in NHL treatment. The age-adjusted incidence rates for NHL in men and women in India are 2.9/100,000 and 1.5/100,000, respectively. Within India, the incidence is several-fold higher in urban cancer registries compared to rural areas; the incidence being higher in metropolitan cities and Indian immigrants suggesting that urban lifestyles and economic progress may increase the cancer incidence. India has an estimated 40,000 sufferers of non-Hodgkin’s lymphoma. The major drivers are large population base and increasing incidence rate, along with government support.
The increasing prevalence of cancers of different forms, including blood cancer will aid the lymphoma treatment market growth during the forecast period. The growing necessity for advanced and effective therapeutics can be a crucial factor in boosting the lymphoma treatment market trends. For instance, lymphomas usually have no to minimal symptoms till the cancer hits the last stage and, in that period, an aggressive and efficient therapeutics is required for better clinical outcomes. Furthermore, the requirement for pre-treatment options to administer advanced therapeutics in patients for the treatment of lymphoma will enable healthy growth of the market in the foreseeable future. In addition, the demand for enhanced and better clinical outcomes for patients will create business opportunities for this market during the forecast period. Lymphoma comprises a sizeable number of blood cancer and the significant number of these cancer has no clinical sign till the disease is in the final stages, a need for more robust treatment methods fuel the growth of this market.